Based on clinical presentation, glioblastoma (GBM) is stratified into primary and secondary types. The protein 53 (p53) allele triggers p53-tumor-suppressor activity. Congruently, growth inhibition upon normalization of mutant p53 by a small molecule, Prima-1, in human GBM cultures also requires p14 ARF /MDM2 functionality. Notably, the antitumoral efficacy of p53 restoration in tumor-bearing GFAP-HRas V12 ;p53 KI/KI animals depends on the duration and frequency of p53 restoration. Thus, intermittent exposure to p53ER TAM activity mitigated the selective pressure to inactivate the p19 ARF /MDM2/p53 pathway as a means of resistance, extending progression-free survival. Our results suggest that intermittent dosing regimes of drugs that restore wild-type tumorsuppressor function onto mutant, inactive p53 proteins will prove to be more efficacious than traditional chronic dosing by similarly reducing adaptive resistance.
Based on clinical presentation, glioblastoma (GBM) is stratified into primary and secondary types. The protein 53 (p53) pathway is functionally incapacitated in most GBMs by distinctive type-specific mechanisms. To model human gliomagenesis, we used a GFAPHRas V12 mouse model crossed into the p53ER TAM background, such that either one or both copies of endogenous p53 is replaced by a conditional p53ER TAM allele. The p53ER TAM protein can be toggled reversibly in vivo between wild-type and inactive conformations by administration or withdrawal of 4-hydroxytamoxifen (4-OHT), respectively. Surprisingly, gliomas that develop in GFAP-HRas allele triggers p53-tumor-suppressor activity. Congruently, growth inhibition upon normalization of mutant p53 by a small molecule, Prima-1, in human GBM cultures also requires p14 ARF /MDM2 functionality. Notably, the antitumoral efficacy of p53 restoration in tumor-bearing GFAP-HRas V12 ;p53 KI/KI animals depends on the duration and frequency of p53 restoration. Thus, intermittent exposure to p53ER TAM activity mitigated the selective pressure to inactivate the p19 ARF /MDM2/p53 pathway as a means of resistance, extending progression-free survival. Our results suggest that intermittent dosing regimes of drugs that restore wild-type tumorsuppressor function onto mutant, inactive p53 proteins will prove to be more efficacious than traditional chronic dosing by similarly reducing adaptive resistance.
preclinical model | Nutlin 3 | intermittent treatment G lioblastoma (GBM) is the commonest and most lethal type of central nervous system neoplasm. Historically, GBMs are classified as primary and secondary glioblastomas, the latter developing from preexisting lower-grade astrocytic tumors. Despite their broadly similar tumor histopathologies, the genetics of human GBM is extremely diverse. Most GBMs appear to be driven by promiscuous activation of the rat sarcoma (Ras) signaling pathway, either through mutation/overexpression of receptor tyrosine kinases (1) or through inactivation of neurofibromatosis (NF1) (2) .
The protein 53 (p53) tumor-suppressor pathway is functionally inactivated in almost all types of human cancer and seems to be a necessary condition for oncogenic activation. Intriguingly, however, the mechanism by which p53-mediated tumor suppression is forestalled varies in differing tumor types. For example, in colorectal, breast, and lung carcinomas, p53 itself is inactivated, either by gene loss or through structural mutation (3) (4) (5) . In contrast, p53 often remains functionally competent in other cancer types, but its activation is blocked by mutations that incapacitate transduction of its upstream activating signals. Thus, overexpression or amplification of mouse double minute (mdm2), the gene encoding the E3-ubiquitin ligase that targets p53 for degradation by the proteasome, is frequent in prostate cancer, whereas overexpression of the p53 transcriptional inhibitor MdmX is common in retinoblastoma (6, 7) . In some breast, brain, and lung tumors, the upstream inhibitor of Mdm2 activity, p14 ARF , is inactivated by gene loss, methylation, or repression (8) (9) (10) (11) (12) , thus uncoupling p53 activation from oncogenic signaling (13, 14) . Finally, in tumors associated with DNA tumor viruses such as HPV, simian vacuolating virus 40, and adenovirus, p53 typically is inactivated directly by viral oncoproteins.
The p53 pathway is functionally inactivated in almost all instances of GBM. However, direct inactivation of p53 itself is relatively rare in primary GBM (15) ; instead, the p53 pathway is compromised by deletion of the Ink 4a /p14
ARF locus or by amplification of mdm2. In contrast, mutations that directly inactivate or delete p53 itself are the norm in secondary GBM (16) . More recent genome-wide systems analyses based on their transcriptome profiles have stratified gliomas into four molecular signatures: proneural, neural, classic, and mesenchymal (2) . Although both oncogenic Ras signaling and inactivation of the p53 pathway are features common to GBMs of all four molecular genetic subgroups, the precise mechanism by which Ras is activated and p53 activation is curtailed varies among the four subtypes. Such differences presumably reflect the differing evolutionary ontogenies of each GBM subtype. These, in turn, intimate that therapeutic strategies may need to be tailored to each form of GBM (17) . Indeed, O6-methylguanine-methyltransferase (MGMT) status (18, Significance Glioblastoma is the most common and aggressive form of brain cancer. GBM patients typically respond poorly to conventional therapies. The tumor-suppressor protein 53 pathway is disrupted in a majority of GBM cases. Using a mouse model that mimics the progression of human GBM, we evaluate and optimize the therapeutic efficacy of functional p53 restoration in gliomas. We show that the efficacy of p53 restoration therapy in the animal model as well as in human GBM cells is improved markedly by an episodic dosing regimen that circumvents the selective pressure for adaptive resistance when p53 function is chronically restored.
19), isocitrate dehydrogenase (IDH1/2) mutation (20) , EGF receptor (EGFR) amplification (21) , and p53 status (22) are all being assessed currently as potential determinants of personalized GBM therapy.
Several strategies for functional restoration of defective p53 pathway signaling in cancers have been proposed, including virusmediated delivery of wild-type p53 in tumors that have lost p53 itself, inhibition of Mdm2 and/or MdmX in tumors that retain functional p53 but in which the activating signal has been disrupted, and, in tumors with inactivating structural mutations in p53, small molecules that restore wild-type p53 conformation (23) (24) (25) . In GBM the standard of care-irradiation and temozolomide-is only moderately effective, and additional approaches are being evaluated (26) (27) (28) , including restoration of p53 function. However, the therapeutic efficacy of specific p53-restoration therapies remains unclear. Clearly, the precise strategy for p53 restoration in any given glioblastoma will need to be tailored to the mechanism by which the pathway has been disrupted. Even then, two caveats remain. First, restored p53 function will be therapeutically effective only if GBMs harbor both sustained and obligate p53-activating signals and if they retain intact downstream p53 effector growth arrest and apoptotic functions. Second, any approach to p53 functional restoration is susceptible to defeat by secondary mutations in the restored p53 pathway. How often such secondary mutations drive relapse depends on the type of mutation responsible for secondary p53 pathway inactivation, itself a consequence of the initial mechanism of p53 pathway inactivation, on the spontaneous frequency with which such mutations arise within the tumor cell population, and on how such secondary mutations fair under the selective pressure imposed by the initial p53 restoration.
In this study, we use a preclinical model of GBM in combination with a switchable p53 allele to model the therapeutic effect of p53 pathway restoration. We show that the therapeutic efficacy of p53 pathway restoration is greatly influenced by both the initial mechanism of p53 pathway-inactivating mutation and by the temporal manner in which the selective pressure elicited by p53 pathway restoration is applied.
Results p53 Deficiency Accelerates Initiation of Harvey Ras
V12 -Driven Gliomagenesis. We modeled gliomagenesis in vivo using GFAPHarvey Ras (HRas) V12 animals, 50% of which develop tumors that are histopathologically similar to human astrocytomas by age 12 wk, with a lifetime incidence of 95% (29 ;p53 KI/KI animals (Fig. 1A) . Despite these significant differences in latency, however, tumors arising from each of the different p53 backgrounds exhibited very similar pathological features, all closely resembling highgrade gliomas in human patients (Fig. 1B) . The high-grade gliomas arising in GFAP-HRas V12 ;p53 +/KI and GFAP-HRas V12 ;p53 KI/KI mice exhibited increased cell density, nuclear polymorphism, infiltrating edges, regions of tissue necrosis, and a high Ki67-labeling index (Fig. 1B) . Although the overall frequency of tumors among the differing p53 backgrounds was similar, p53-deficient animals exhibited accelerated formation of high-grade gliomas relative to p53 wild-type and p53 hemizygous backgrounds (Fig. 1C) . Hence, a functional p53 pathway retards the evolution of HRas
V12
-driven glial tumorigenesis. +/KI animals is by far the most common mechanism of p53 pathway inactivation (34) (35) (36) (37) . For example, Eμ-myc-driven lymphomas arising in p53 +/KI mice invariably inactivate the wildtype copy of p53, and subsequent restoration of the second, 4-OHT-dependent p53ER TAM allele triggers dramatic p53-dependent apoptosis and tumor regression and significantly extends overall survival (37) .
We reasoned that if the single wild-type p53 allele is inactivated during GFAP-HRas V12 ;p53 +/KI tumor progression, then restoration of the remaining conditional p53ER TAM allele to wild-type function should impact tumor maintenance and subsequent progression. To address this notion, TAM, which is metabolized to the active 4-OHT ligand in vivo, was administered to symptomatic GFAP-HRas V12 ;p53 +/KI animals to restore p53 function, and the impact on survival was monitored. Surprisingly, restoration of function to the p53ER TAM allele afforded no significant benefit in overall survival ( Fig. 2A) (Fig. S1A) . Consistent with this finding, the restoration of p53 activity in explanted tumors in vitro by 4-OHT did not affect the proliferation nor viability of tumor cells (Fig. 2F ) or the expression of bona fide p53 target genes (Fig. S1B) .
Although one possible explanation for the lack of impact of TAM in GFAP-HRas V12 ;p53 +/KI tumors is that the 4-OHTdependent p53ER TAM allele had been inactivated in some way, it also is possible that the gliomas lack a requisite signal to activate p53ER TAM once it has been functionally restored by TAM. In the latter scenario, functionally restored p53ER TAM still should cause growth arrest and/or apoptosis in response to some other signal, for example, DNA damage (Fig. 2D) . To determine the status of both p53 and p53ER TAM in tumors arising in GFAPHRas
;p53 +/KI mice, tumor-bearing animals were exposed to 7 Gy of γ-radiation to activate p53 directly. As a comparison, we also irradiated tumor-bearing p53 KI/KI mice, which are totally deficient for p53 activity in the absence of TAM. Tumors from all irradiated animals then were analyzed for DNA damage-induced apoptosis by immunohistochemical staining for activated caspase 3 (Fig. 2E) . Radiation-induced apoptosis was absent from tumors derived from GFAP-HRas V12 ;p53 KI/KI mice treated with vehicle control but was evident once p53ER TAM had been functionally restored by administration of TAM, thus confirming that such apoptosis is p53 dependent (Fig. S1C) . Radiation-induced apoptosis (3.75% of total tumor cells) was evident in the gliomas arising in GFAP-HRas V12 ;p53 +/KI mice irrespective of whether TAM was administered, indicating that the wild-type p53 allele was still functional (Fig. 2E) . Similarly, radiation-induced apoptosis and the induction of p53 target genes was apparent in cultured glioma cells derived from p53 +/KI mice irrespective of 4-OHT (Fig. 2G) but not in the wild-type p53-deficient tumor cells from p53 KI/KI mice. In the latter case, both apoptosis and post-irradiation induction of the p53 target genes puma and cyclin-dependent kinase inhibitor 1a CDKN1A were evident only when 4-OHT was added to the medium (Fig. S1 D and E) . Thus, the p53-dependent, DNA damage-induced apoptotic pathway remains intact in GFAP-HRas V12 ;p53 +/KI tumors. Furthermore, DNA sequence analysis confirmed that the wild-type p53 allele in such tumors harbored no detectable mutations. Hence, gliomas arising in GFAP-HRas
;p53 +/KI retain their functional wild-type p53 allele.
Because p53 in GFAP-HRas V12 ;p53 +/KI tumors remains functional and is responsive to DNA damage, the likely explanation for its inactivity is the absence of an upstream signal to activate p53 in response to oncogenic signaling. The principal mediator of such oncogenic activation of p53 is the tumor suppressor p19 ARF (p14 ARF in humans), which is specifically induced by aberrantly elevated flux through oncogenes such as Myc and Ras (38, 39) and acts to antagonize the p53-suppressive action of Mdm2 (40, 41) . This pathway may be incapacitated either through loss of p19 ARF itself or by overexpression of Mdm2 (Fig.  2D ). To determine whether the p19 ARF /MDM2 regulatory pathway is functionally compromised in GFAP-HRas V12 ;p53 +/KI gliomas, we used Nutlin 3, a pharmacological inhibitor of Mdm2, to probe its functionality. Nutlin 3 induced significant apoptosis in disaggregated tumor cells from two independent GFAPHRas V12 ;p53 +/KI tumors irrespective of the presence of 4-OHT (Fig. 2H ). This effect was completely p53 dependent ( Retain Persistent p53-Activating Signals. The studies described above all modeled the evolution of gliomas in which sporadic Ras pathway activation precedes p53 pathway inactivation, and they show that, when functional p53 itself is present, Ras activation drives selection that retains functional p53 in favor of other p53 pathway-inactivating mutations. To model the alternative evolutionary path, in which sporadic p53 loss precedes or coincides Ras activation, Ras-driven gliomas were allowed to form in GFAP-HRas
;p53 KI/KI mice, which, in the absence of TAM, are functionally p53 null. To ascertain whether both p53-activating signals and downstream p53-mediated tumor-suppressor pathways remained competent in such tumors, we used TAM to restore p53ER TAM functionally and assayed any effects of such restoration. Indeed, restoration of p53 triggered a dramatic drop in tumor cell proliferation-the proportion of actively proliferating BrdU-positive tumor cells fell from 13.3% before p53 restoration to 1.1% after p53 restoration ( (Fig. 3D ). TAM treatment of mice (p53ER-Restored) also rapidly led to a reduction in neurological deficits in animals and increased general health (Movies S1 and S2). Because p19
ARF is a crucial upstream regulator of p53 activity, we assayed p19
ARF expression in the tumors before (p53ER OFF) and 24 h after p53 restoration by addition of TAM (p53ER-Restored). The percentage of the p19 ARF -positive cells in tumors fell from 32.2 to 5.67% following restoration of the p53ER allele (Fig. 3E) ;p53 KI/KI mice and then maintained p53 function for 10 subsequent weeks by daily injection of TAM (Fig. 4A) . At this point, any symptomatic animals were presumed to harbor secondarily p53-resistant tumors. To determine whether such resistant tumors retain functional p53, symptomatic TAM-treated animals were treated with Nutlin 3 for 48 h to activate any functional p53 present, and then tumors were harvested and assayed for apoptosis. Nutlin 3 induced apoptosis (7.59% of total tumor cells) in the tumors (Fig. 4B ), confirming that p53 (and its downstream apoptotic effectors pathway) remains functionally intact.
Because p53 is functional in these tumors, we reasoned again that its failure to block tumor growth was likely caused by the interruption of upstream p53-activating signals. Because p19 ARF is the mediator of oncogenic Ras signaling (39, 42), we assayed p19 ARF expression in both previously untreated tumors (p53ER OFF) and in tumors subjected to sustained restoration of p53 for 10 wk (p53ER-Restored Sustained) ( TAM allele restoration is shown. A single dose of TAM was administered i.p. to symptomatic animals (p53ER Restored), and a single dose of vehicle was administered to control (Ctrl) animals (p53ER OFF). BrdU was administered 22 h later, and tissues were harvested 2 h after BrdU administration. (D) Schematic representation of the p53 tumor-suppressor pathway. Activated oncogene(s) (and other potential signals) induce expression from the alternate reading frame (ARF) of the CDKN2A gene, whose product, p19 ARF , stabilizes and activates p53 by blocking the p53 inhibitor MDM2. Activated p53 then executes its principal tumor-suppressive activities, i.e., induction of apoptosis and/or growth arrest. Loss of the ARF locus or up-regulation of MDM2 inactivates the functional p53 pathway. In such settings, p53 activity might be restored by the induction of an alternative p53-activating signal (e.g., DNA damage) or by pharmacological inhibition of MDM2 (e.g., by Nutlin 3). (E) Immunohistochemical analysis of cell death assayed by staining for activated caspase 3 in GFAP-HRas Optimizing of p53 Restoration Therapy. Our data indicate that restoring p53 function can exert a profound initial therapeutic impact in gliomas that evolve in the absence of functional p53. However, that therapeutic impact is eroded rapidly by the emergence of secondarily p53-resistant tumor clades that outgrow in the face of the selective pressure imposed by p53 restoration. It is known that both the rate at which adapted species arise and the evolutionary mechanism by which they do so can be influenced profoundly by whether selection is sustained or episodic (43) . Given that sustained p53 restoration in GFAPHRas 
Relapse after transient p53 restoration might be caused by the outgrowth of tumor cells harboring mutations that confer resistance to p53ER TAM restoration, in which case the recurring tumors should be resistant to subsequent p53 restoration. Alternatively, relapse might be caused by the resumed growth of a subpopulation of tumor cells that, although still sensitive to p53 restoration, undergo reversible growth arrest instead of apoptosis. In this latter case, the recurring tumors should remain responsive to subsequent p53 restoration. To distinguish between these two possibilities, 21-d-old GFAP-HRas V12 ;p53 KI/KI mice were subjected to a single, transient p53 restoration, which, as indicated previously, significantly delayed tumor outgrowth. The animals were monitored daily for neurological deficits indicative of astrocytoma development. Then p53 function was restored again in the symptomatic (tumor-bearing) GFAPHRas V12 ;p53 KI/KI animals, and its impact on tumor apoptosis was assessed. Intriguingly, the delayed tumors remained responsive to p53 restoration, exhibiting dramatic p53-dependent apoptosis (Fig. 5B) . However, because GFAP-HRas V12 animals might develop gliomas throughout their lifespan, the possibility existed that these delayed tumors exhibited p53 sensitivity because they had arisen de novo rather than surviving outgrowth from the original tumors. Therefore, to confirm that outgrowths from original p53-sensitive tumors subjected to transient p53 restoration indeed are sensitive to subsequent p53 restoration, we transplanted GFAP-HRas V12 ;p53 KI/KI tumors intracranially into congenic p53 KI/KI recipients and then subjected the recipient animals to a single episode of p53 restoration. Just as in the autochthonous tumors, the growth of transplanted tumors was delayed but not prevented (Fig. S5A) . Moreover, the reemerging transplanted tumors remained largely responsive to p53-induced apoptosis following subsequent restoration of p53ER TAM allele (Fig. S5B) , supporting the notion that a single transient restoration of p53 in tumors does not convey resistance to the successive restoration of p53 activity. Hence, unlike tumors evolving in the presence of sustained p53 restoration, tumors recurring after a single, transient restoration of p53 function retain responsiveness to subsequent p53 restoration.
We hypothesized that p19 ARF , as the principal mediator of p53 activation in GFAP-HRas V12 ;p53 KI/KI gliomas, also was expressed in tumors arising after a single transient restoration of p53. To investigate this hypothesis, we compared expression of p19 ARF in tumors harvested from previously untreated, symptomatic GFAP-HRas V12 ;p53 KI/KI mice ("naive tumors") and from animals that succumbed to the disease after a single transient restoration of p53 at the age of 21 d (1× TAM). The tumorbearing animals were injected with BrdU to label actively proliferating cells and were given a control vehicle or a single dose of TAM 4 h later to restore p53 transiently. Both naive tumors and tumors that reemerged after a single exposure to TAM at the age of 21 d contained p19
ARF ;BrdU double-positive cells (36.4% and 30.2% respectively) before transient restoration of p53 activity (Fig. 5C ). The percentage of p19 ARF ;BrdU doublepositive cells dropped significantly (8.6% and 6.98%, respectively) 20 h after restoration of p53 function (p53ER-Restored), suggesting that most of the actively proliferating p19 ARF -positive cells in both naive tumors and tumors arising in animals after transient p53 restoration (1× TAM) presumably are eliminated by apoptosis when p53 is restored for 24 h (p53ER Restored). Moreover, any remaining p19
ARF -positive cells still present in both the naive and 1× TAM tumors were all Ki67 negative (Fig.  5D ), indicating their growth arrest.
Having established that tumors recurring after a single, transient restoration of p53 remain largely responsive to a second round of p53 restoration, we next asked whether repeated, in- ;p53 KI/KI animals was subjected to transient p53 restoration (a single TAM injection) once a week for 10 wk. Remarkably, more than 80% of such intermittently treated mice remained symptom-free, surviving beyond 100 d (Fig. 5E) .
The significant survival benefit afforded by intermittent transient p53 restoration over sustained p53 restoration suggests that, as with tumors remerging after single transient p53 restoration at age 21 d (1× TAM), the tumors retain p53 sensitivity throughout subsequent rounds of p53 restoration. To confirm this possibility, we assayed induction of apoptosis after repeated rounds of p53 restoration. Seven-week-old asymptomatic animals previously subjected either to a single dose of TAM at age 21 d (1× TAM) or to three sequential rounds of treatment with TAM once a week, starting on day 21 and with the last injection occurring at age 5 wk (Intermittent TAM), were treated with TAM (p53ER-Restored). Tissues were harvested 24 h after the last p53 restoration. After the transient restoration of p53 activity we detected similar levels of apoptosis in the lesions (8.8% and 6.8%, respectively) (Fig. 5F ).
Because the presence of a functional p19 ARF /MDM2 regulatory branch is crucial for oncogenic activation of p53 tumor-suppressor response, we ascertained the status of p19 ARF expression in tumors subjected to intermittent restoration of p53. Brain samples for analysis were collected from 7-wk-old asymptomatic animals previously treated with a single dose of TAM at age 21 d (1× TAM) or with three sequential rounds of TAM once a week starting at age 21 d, with the last injection occurring at 5 wk of age (Intermittent TAM). Notably, and in contrast to the tumors reemerging during sustained restoration of p53 (Fig. S4) , tumors reemerging in animals subjected to a single transient restoration of p53 at age 3 wk and those reemerging in animals after repeated intermittent p53 restoration retained p19 ARF expression in actively proliferating, Ki67-positive tumor cells (Fig. S6) . Taken together, these data indicate that, unlike sustained restoration of p53, the repeated transient imposition of p53 restoration negates the otherwise strong selective advantage afforded by p53-pathway ablation in gliomas arising in GFAP-HRas V12 ; p53 KI/KI mice, thereby significantly enhancing the durability of the therapeutic response to p53 restoration.
Restoration of p53 Activity in Human Glioma Cultures. The GFAPHRas V12 ;p53 +/KI and GFAP-HRas V12 ;p53 KI/KI mouse models of gliomagenesis mimic two different scenarios of human glioma progression. In both, the p53 pathway is incapacitated. In GFAPHRas V12 ;p53 +/KI mice, Ras activation precedes p53 pathway inactivation, and functional p53 is retained in favor of mutations that inactivate the upstream p53-activating signal. In contrast, in the GFAP-HRas V12 ;p53
KI/KI mouse model, in which loss of p53function (resulting from the absence of 4-OHT) precedes or coincides with Ras activation, both upstream p53-activating signals and downstream p53-mediated arrest and apoptotic pathways remain intact. Only in this latter case would restoration of p53 function be expected to have any growth-suppressive effect. Notably, these distinctive mouse models phenocopy the two predominant modes of p53 pathway disruption in high-grade human gliomas: 42% retain functional p53 and lose ARF (p53WT;CDKN2A (ARF) MT), whereas ∼20% inactivate p53 directly and retain ARF (p53MT; CDKN2A(ARF) WT) (refs. 2 and 17 and Fig. 6A) .
To model the therapeutic impact of p53 restoration in human gliomas of each class, we exposed human GBM cell lines (44) to 2, 2-bis(hydroxymethyl)-3-quinuclidinone (Prima-1), a smallmolecular-weight compound that restores the defective conformation of mutant p53, rescuing competence for both DNA binding and activation of p53 target genes (45) . Human GBM cell lines carrying either wild-type p53 (p53WT) or mutated copies of p53 (p53MT) in combination with either competent CDKN2A (CDKN2A WT) or deleted CDKN2A (CDKN2A MT) were exposed to Prima-1 (5, 10, or 20 μM) or control vehicle for a period of 1, 3, or 5 d, and effects on cell proliferation and p53 target gene induction were ascertained. At the concentration used (20 μM), Prima-1 elicited only minor p53-independent effects (proliferation of p53WT tumors fell by 14% upon Prima-1 exposure) (Fig. 6B) . In contrast, Prima-1 exposure induced significant growth inhibition (98% reduction in cell proliferation) in glioma cells harboring mutant p53, but only if they also retained CDKN2A(ARF) (Fig. 6B) . The antiproliferative effect of Prima-1 coincided with the induction of p53 target genes [CDKN1A (p21 cip1 ), mdm2, and growth arrest and DNA damage gene 45a (gadd45a)] (Fig. 6C) . This increased sensitivity of CDKN2A (ARF)-competent GBM cells to Prima-1 as compared with CDKN2A-deficient GBM cells was confirmed by analysis of an independent set of human primary GBM cultures (Fig. S7) . Our data suggest that in human GBMs, as in gliomas arising in GFAP-HRas V12 ;p53 KI/KI mice, the presence of functional p53-activating signals is crucial to educe the p53 tumor-suppressor activities upon p53 restoration.
We next sought to determine whether in human GBM cell lines intermittent reactivation of p53 circumvents acquired resistance to p53-restoration therapy, similar to effect of intermittent p53 reactivation in the conditional mouse model. We propagated human GBM cell lines harboring mutant p53 but wild-type CDKN2A(ARF) in the presence of sustained or in- Fig. 4C is presented as the percentage of total tumor cells. At least four animals were analyzed for each treatment. Immunohistochemical analysis was performed in duplicate; 10 randomized fields per staining were considered. ***P ≤ 0.001; ns, no statistical significance. Statistical analyses were performed using a two-tailed Student t test.
termittent exposure to Prima-1 at two different concentrations (10 and 20 μM) for a duration of 7 wk. At the end of the treatment, the cells were allowed to expand in Prima-1-free medium for an additional week. The resulting "sustained" and "intermittent" cultures were exposed to 0, 5, 10, and 20 μM of Prima-1 for 72 h, and effects on cell proliferation were measured. Reintroduction of Prima-1 induced a significant reduction of proliferation in GBM cultures that were propagated under intermittent exposure to Prima-1 but not in cultures subjected to sustained exposure to Prima-1 (Fig. 6D) . This resistance of human GBM cells to chronic Prima-1 exposure was characterized by the loss of CDKN2A(ARF) mRNA and protein expression (Fig. 6 E and F) . Our data show that in human GBM cell lines, as in the GFAP-HRas V12 ;p53 KI/KI mouse model, transient exposure to p53 activity significantly prolongs therapeutic response to a treatment aimed to restore p53 function.
Discussion
Emerging evidence suggests that primary and secondary GBMs exhibit different patterns of genetic alterations, reflecting their distinct etiologies and potentially influencing their responsiveness to certain therapies, in particular therapies targeting specific molecular pathways (22) . Alterations that diminish or abrogate the functions of the p53 tumor-suppressor pathway are seen in both primary and secondary GBM. However, p53 pathway dysfunction arises by different mechanisms in each of the two GBM subtypes. Loss of p53 itself through inactivating mutations is an early event in the multistep development of about two thirds of secondary GBM (46) . In contrast, in primary GBM the p53 tumor-suppressor pathway is incapacitated most frequently by the deletion of the Ink4/ARF locus or by overexpression of MDM2, rather than by loss or mutational inactivation of p53 itself (15, 16, 47) .
Using mice in which the GFAP-HRas V12 transgene is combined with either hemi-or homozygosity for a conditional allele of p53 (p53 KI/KI ), we modeled the evolution of these two distinct subtypes of gliomas and ascertained the therapeutic potential of p53-based therapy in each. Although human GBMs rarely display HRas v12 mutations, the elevated activity of constitutively expressed HRas V12 produces elevated levels of MAPK pathway activation comparable to those observed in human GBMs with either EGFR or PDGF receptor A/B (PDGFR-A/B) amplification and/or activating mutations, which are common driver oncogenic mutations in human GBM (31, 48) . GFAP-HRas V12 ; p53 KI/KI mice, in which p53 is inactive throughout Ras-induced gliomagenesis, mimic the evolution of human gliomas wherein p53 itself is inactivated at the outset of tumor progression. We observed that the absence of functional p53 significantly accelerated Ras-induced gliomagenesis, consistent with the recently demonstrated role played by p53 inactivation in the progression of astrocytomas in humans (49) . Functional restoration of p53 in such tumors triggered immediate p53 activation, arrest of tumor cell growth, and apoptosis, indicating that both upstream p53-activating signals and downstream tumor-suppressor effectors for apoptosis and growth arrest remained intact when p53 function was missing throughout tumorigenesis. By analogy, we predict that p53-restoration therapies are likely to be efficacious in human GBM in which p53 is inactivated early in tumor evolution.
In contrast, malignant astrocytomas developing in GFAPHRas
V12
;p53 +/KI mice (in which one p53 allele is wild type) ;p53 KI/KI tumors reemerging in animals after a single treatment with TAM at age 3 wk (1× TAM), compared with tumors from animals subjected to three rounds of p53 restoration once a week starting at age 3 wk (Intermittent TAM). The percentage of apoptotic cells in tumor area is indicated. 1× TAM, n = 6; Intermittent TAM, n = 4 treatment. Immunohistochemical analysis was performed in duplicate; 10 randomized fields were considered. Lateral ventricles (LV), corpus callosum (cc), and tumor area (T) are indicated. (Scale bars: 50 μm.) model the evolution of human tumors, such as primary GBMs, in which Ras activation precedes the loss of a functional p53 pathway (13) . In such tumors restoration of p53 function is therapeutically irrelevant, because selection against the p53 pathway preferentially elicits either loss of p19 ARF or up-regulation of Mdm2, rather than direct inactivation of p53 protein itself as observed in the (cis)p53 +/− ;NF1 (+) flox/flox ;hGFAP-crepositive model (50) . These results highlight the mutual complementarity of the two models. Indeed, human glioblastomas deficient for NF1 activity exhibit relatively low levels of total and phospho-proteins in the PI3K and MAPK pathways, indicating oncogene-signaling activity, as compared with GBMs carrying elevated expression of and/or mutations in EGFR or PDGFR A/ B (48) . Although restoration of functional p53 is inconsequential for p53-competent tumors, activation of p53 by Nutlin 3, an Mdm2 inhibitor, has been proven to induce cell death in these tumors (Fig. 2I ). For gliomas with wild-type p53 status, either Nutlin 3 itself or other inhibitors of Mdm2 activity potentially can be translated into clinical settings. Unfortunately, it is impossible to predict whether in these tumors an intermittent regimen of Mdm2 inhibition in gliomas will be as efficacious as the intermittent restoration of p53 in the p53-deficient lesion. The resistance of tumor cells to treatments based on Mdm2 inhibition might be achieved by mechanisms other than resistance to p53 restoration (e.g., Mdm2 amplification).
We evaluated the potential impact of p53 restoration in human GBM cell lines that carry p53 gene mutations by using a smallmolecular-weight molecule, Prima-1, that selectively restores sequence-specific DNA-binding activity to mutant forms of p53 protein. As in the GFAP-HRas V12 -driven gliomas, the restoration of p53 activity inhibited human GBM cell proliferation. However, as in the GFAP-HRas V12 -driven gliomas, the p53 tumor-suppressor activity and the induction of p53 transcriptional targets following exposure to Prima-1 were detected only in tumors in which the p53-activating branch (p14 ARF /MDM2) remained intact ( Fig. 6 B and C and Fig. S7 ). Moreover, in human GBM cells the selective pressure against the p53 pathway imposed by sustained exposure to Prima-1 results in the loss of p14 ARF expression and subsequent resistance to the drug treatment (Fig. 6 D-F) . Around 11% of all human GBMs contain mutations in both the p53 gene and its activating tumor-suppressing branch, p14 ARF /MDM2, as was established recently by the molecular profile of human GBMs (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp and ref.
2). Our data suggest that restoration of p53 activity by Prima-1 alone [or by other small molecules modulating the DNA-binding activity of mutant p53 (51)] is not sufficient to induce p53 tumor-suppressor activity in these doubly mutant patients, and alternative means of p53 activation (e.g., DNA damage) should be considered for therapeutic intervention based on p53 restoration.
Given the prospect of using such p53-restoration therapies in GBM patients, we went on to use the GFAP-HRas V12 ;p53 KI/KI model to assess potential regimens for p53 restoration in the p53-mutant fraction of gliomas. In GFAP-HRas V12 ;p53 KI/KI tumors, sustained restoration of p53 function rapidly selects for the emergence of tumor cell populations resistant to p53 function by virtue of abrogating p53-activating signals, i.e., loss of p19 ARF or amplification of MDM2. Further analyses established that there is a significant difference between tumors subjected to sustained p53 restoration and the tumors that developed in GFAP-HRas V12 ;p53 KI/KI animals after a short-term restoration of p53 activity. The latter emerge faster (Figs. 4A and 5A ) and, surprisingly, retain p19 ARF /MDM2 signaling (Fig. 5B) . Thus, it appears that losing p19 ARF does not convey growth or survival advantage to the Ras-driven tumors that have developed in the context of inactive p53 until p53 function is chronically restored. In marked contrast to the resistance mediated by the loss of p19 ARF in chronically p53-restored tumors, the tumors remerging after a brief period of p53 restoration do not develop such resistance, as evidenced by their susceptibility to undergo apoptosis and replicative growth arrest subsequently in response to additional rounds of transient p53 restoration.
Taken together, our data imply the existence of three populations within the GFAP-HRas V12 ;p53 KI/KI tumors, each with a distinct response to p53 restoration. Two of these populations are sensitive to p53 restoration: one, comprising the bulk of tumor cells, responds to p53 restoration by apoptosis and/or permanent replicative arrest. A second, smaller, population also is responsive to p53 restoration but instead of dying undergoes viable and reversible replicative arrest. Once p53 function is removed, this second population regenerates the tumor. Clearly, the refractoriness of this second population to p53-induced apoptosis is not a heritable trait, because the bulk of cells within the tumors from which it regenerates are, once again, susceptible to p53-induced apoptosis. Possibly such resistant glioma cells represent an innately apoptosis-resistant tumor stem cell population or, alternatively, cancer cells transiently residing in a protected somatic niche. The trivial possibility that some tumor cells survive p53 restoration through lack of exposure to 4-OHT seems unlikely, given the ubiquitous restoration of p53 that we have observed following systemic administration of 4-OHT to p53 KI/KI mice, the facile capacity of 4-OHT to cross the blood-brain barrier, and the persistence of 4-OHT in plasma for up to 24 h following the administration of a single bolus (52, 53) . In addition to these p53-sensitive populations, there evidently is a third population of tumor cells that harbors a preexisting secondary p53 pathway-inactivating mutation and that therefore is innately unresponsive to p53 restoration.
The eventual outgrowth of this third population of p53-resistant tumor cells and the p53-resistant tumor they regenerate limits how long survival may be extended by periodic p53 restoration. Hence, factors that govern the rate of outgrowth of this population will be critical in determining the overall therapeutic efficacy of p53 restoration. Although sustained p53 restoration affords a selective advantage only to innately p53-resistant tumor cells, transient p53 restoration (once relaxed) permits the outgrowth of both innately p53 resistant tumor cells and those tumor cells that are only adventitiously refractory to p53-induced apoptosis. Perhaps competition between these two populations or the differential activity of Ras signaling in tumor cells mitigates the outgrowth of the resistant tumor cells (Fig. S8) . We suspect that these mechanisms underlie the greater therapeutic efficacy of intermittent versus sustained p53 restoration. However, although an intermittent regimen of a p53-reactivating treatment significantly lengthened the lifespan of tumor-bearing animals, we nonetheless detected tumors in all the intermittently treated animals surviving beyond 100 d, and all animals from the independent cohort left for surveillance following cessation of intermittent treatment eventually succumbed to disease. Hence, intermittent p53 restoration typically delays, rather than stops, disease progression. As is consistent with this effect, the human GBM cultures maintained under intermittent exposure to Prima-1 continue to proliferate once the drug is removed. These data suggest that the application of therapy based on p53 restoration in combination with other antiglioma strategies, for example conventional GBM therapies such as temozolomide, will be more beneficial for patients than temozolomide alone. In particular, patients with secondary GBMs exhibiting a high frequency of p53 mutations and displaying MGMT promoter silencing (46) , which is crucial for the tumor sensitivity to temozolomide (18) , could be regarded as ideal candidates. Nevertheless, our data predict a significant therapeutic advantage for intermittent versus sustained regimens of p53-restoration therapy, making intermittent therapy worthy of serious consideration in future clinical trial designs involving p53-reactivating agents. (33) . Mice were sacrificed either when they exhibited symptoms of neurological distress or at established time points. For irradiation studies, mice were exposed to 7 Gy γ-radiation using a Mark 1-68 137 Cesium source (0.637 Gy/min). To inhibit MDM2 pharmacologically, mice were treated with Nutlin-3 (Cayman Chemical) administered orally through gavage (200 mg/kg), initially 24 h before administration of 4-OHT and subsequently twice each day during p53 restoration. Tissue samples were harvested 24 h after the administration of 4-OHT. Brain tissues were embedded in Optimum Cutting Temperature (OCT) medium (Sakura Finetek) or paraffin for immunohistochemical and histological H&E analyses.
Materials and Methods
Histology and Immunofluorescence. Analysis of tumor pathology was performed on the H&E-stained 5-μm paraffin-embedded brain tissue sections. Tumor grade was assigned using the World Health Organization grading scheme (54) . Infiltrating gliomas were considered grade III if they exhibited mitotic figures in tumor cells. Identification of tumor necrosis or endothelial proliferation was sufficient to categorize tumors as GBM-like. Areas with increased proliferation but without the obvious nuclear pleomorphism or other features of clearly neoplastic astrocytes were classified as "astrocyte proliferation." Such astrocyte proliferation was confirmed by Ki67 staining. For immunohistochemistry, 20-μm OCT-embedded brain tissue sections were fixed for 30 min in 1% paraformaldehyde solution. The following primary antibodies were used: rabbit monoclonal anti-Ki67 (SP6; Neomarkers), rabbit polyclonal anti-active-caspase 3 (AF 835; R&D), rat monoclonal anti-p19 ARF (C3; Novus), mouse monoclonal anti-BrdU (11 299 964 001; Roche), rat monoclonal anti-BrdU (OBT0030S; Accurate Chemicals), mouse monoclonal anti-GFAP (610565; BD), and rabbit polyclonal anti-ER (MC-20, SC-542; Santa Cruz). All antibodies were applied in blocking buffer [5% (wt/vol) BSA, 2.5% (vol/vol) goat serum] for 2-16 h. Secondary antibodies (Dako and Molecular Probes) were applied in blocking buffer for 1 h. TUNEL staining was performed using the Apoptag fluorescein-labeled kit (Chemicon) according to the manufacturer's directions. Fluorescent images were obtained using an LSM510 confocal microscope (Zeiss) or an Axiovert 100 inverted microscope (Zeiss) equipped with a Hamamatsu Orca digital camera, running Open Lab 3.5.1 software (Improvision).
Immunoblotting. Primary mouse cell culture was performed as described in SI Materials and Methods. Primary mouse tumor cultured cells and mouse astrocytes were frozen as a cell pellet at −80°C, lysed in buffer (50 mM Tris, 150 mM NaCl, 20 mM EDTA, 0.5% Nonidet P-40) supplemented with protease and phosphatase inhibitors, and centrifuged at 20,000 × g for 15 min at 4°C. Protein concentration was determined with the Bio-Rad protein assay. Protein lysates were run in 4-20% gradient gels (Invitrogen) and were blotted onto PVDF membranes (Immobilon-P). Membranes were probed with anti-Mdm2 (SMP14; BD Pharmigen), p14 ARF (4C6/4; Cell Signaling), and anti-β-actin (AC-15; Sigma).
Taqman Analysis and p53 Sequencing Analysis on the Mouse Tumors. Total RNA was isolated using TRIzol reagent (15596-018; Invitrogen) according to the manufacturer's protocol and DNase treated (18068-015; Invitrogen) before reverse transcription (iScript; Bio-Rad). Taqman analysis was performed by the University of California, San Francisco Comprehensive Cancer Center Genome Analysis core facility. All data were normalized to β-glucuronidase (gus) expression. The following probes were used: for mouse p21, Mm00432448_m1 (Applied Biosystems); for mouse PUMA, Mm00519268_m1 (Applied Biosystems); and for mouse mdm2, Mm00487656_m1 (Applied Biosystems). For p53 sequencing analysis, cDNA was amplified with primers p53 forward: 5′-CCA TGG AGG AGT CAC AGT CG-3′ and p53 reverse: 5′-GCA GAG GCA GTC AGT CTG AGT C-3′ as described (37) .
Human Glioma Cell Lines. Human glioma cell lines LN18 and LN215 were kindly provided by M. Hegi (University Hospital of Lausanne, Lausanne, Switzerland). U87MG was obtained from American Type Culture Collection. The p53 and p14
ARF status in these cell lines was described previously (44) . U87MG has wild-type p53, LN215 has a p53 deletion 191-192, and LN18 has a p53 mutation at C238S. U87MG is p14
ARF null, LN215 is p14 ARF wild type, and LN18 is p14 ARF null. All cells were cultured in DMEM with 10% (vol/vol) FCS. For analysis of tumor cell proliferation, glioma cell lines were plated at 3,000 cells per well in 96-well BD Falcon white/clear plates (353377; BD Bioscience) and were cultured for 1, 3, and 5 d with 0, 5, 10, and 20 μM Prima-1 (Cayman Chemical). Cell viability was analyzed by the Cell Titer GloR luminescent assay (G7570; Promega). Experiments were done in triplicate.
To generate sustained and intermittent Prima-1-treated cell populations of LN 215 cell cultures, LN 215 cells were cultured for 7 wk in the presence of 10 or 20 μM Prima-1. For weekly treatment, Prima-1 was added to the cells for 24 once a week h. Twenty-four hours later the cells were washed once in 1× PBS, and fresh drug-free medium was added. For daily treatment, the cells were exposed to Prima-1 continuously, and the medium containing
